Kalbe Farma Tbk

klbf

Overview

KLBF Overview

PT Kalbe Farma Tbk is an Indonesia-based company, which is engaged in the development, manufacturing and trading of pharmaceutical products including human medicines and consumer health products. Its business divisions include Prescription Pharmaceutical, Consumer Health Division, Nutritionals, and Distribution and Logistic divisions. The Prescription Pharmaceuticals division provides a range of products for all groups, from unbranded generic drugs for the mass-market segment, to branded generics and licensed drugs. The Consumer Health division's product portfolio spans from over the counter (OTC) drugs and energy drinks to a selection of ready-to-drink healthy beverage products. The Nutritional division manages a range of nutritional products, comprising of powdered milk products for all age segments. It also offers a selection of non-milk nutritional products. The Distribution and Logistics Division operates the distribution coverage for pharmaceuticals products in Indonesia.

51015ValueCompetitiveFutureFinancialsDividend
Exchange
Indonesia Stock Exchange

Symbol: KLBF

Main
Market Cap.
IDR 68.46Trillion
#26 in Indonesia

~$4.36B USD

Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Sector
Healthcare

Valuation

KLBF Valuation Metrics

1,480

IDR

Closing Price on 2024-04-05

Price to Equity

23.12

P/E

At 23.12x P/E TTM, KLBF.JK is trading at a premium to its peers in the Pharmaceuticals & Health Care Research sector (avg 8.9x).

Price to Book

3.31

P/B

At 3.31x P/B TTM, KLBF.JK is trading at a premium to its peers in the Pharmaceuticals & Health Care Research sector (avg 1.3x).

Price to Sales

2.26

P/S

At 2.26x P/S TTM, KLBF.JK is trading at a premium to its peers in the Pharmaceuticals & Health Care Research sector (avg 0.8x).

Valuing Kalbe Farma Tbk based on its trailing twelve months (TTM) valuation metrics against its peers in the Pharmaceuticals & Health Care Research sector

Historical Price to Earnings

Other Valuation Metrics

Valuing Kalbe Farma Tbk relative to other stocks in the Pharmaceuticals & Health Care Research sector

Price/Cash Flow
31.52x
Price/Forward Earnings
21.49x
Enterprise Value/Revenue
2.20x
Enterprise Value/EBITDA
15.39x
PEG Ratio
-0.63x

Analyst Ratings

40
60
80
0
100

50.0

Undervalued

Fairly Valued

Overvalued

Last closing: IDR1,4802024-04-05
IDR 1,088.63

Slightly Lower Intrinsic Value: Analyst's intrinsic value is of KLBF is IDR1,089, which is 25% lower than KLBF's last closing price of IDR1,480 (as of 2024-04-05).

Valuation Recap of KLBF stock
WeightNotesScore
High
The P/E ratio is calculated by dividing the market price of a company's stock by its earnings per share (EPS). It is a key tool for investors and analysts to assess whether a stock is overvalued, undervalued, or fairly valued. A P/E ratio of 23.12x is above the ID market average of 8.22x and is trading at a premium to peers in the Pharmaceuticals & Health Care Research sector (8.87x). In fact, less than 25% of its peers trade at a higher P/E ratio than KLBF.
Max 3
High
The P/B ratio is calculated by dividing the market price of a company's stock by its book value per share (BVPS). It measures the company's stock value relative to its assets minus liabilities. A P/B ratio of 3.31x is above the peers average of 1.29x in the Pharmaceuticals & Health Care Research sector. KLBF trades at a higher P/B ratio than >75% of its peers in the Pharmaceuticals & Health Care Research sector.
Max 3
Medium
The P/S ratio is calculated by dividing the market price of a company's stock by its sales per share. It measures the company's stock value relative to its sales. A P/S ratio of 2.26x is above the peers average of 0.80x in the Pharmaceuticals & Health Care Research sector. When considered alongside the Forward Price/Earnings ratio, they serve to illustrate investors' expectations of KLBF's valuation relative to its current sales and future earnings growth. KLBF trades at a Forward P/E ratio of 21.49x, which is considered richly valued by analysts.
Max 2
Low
The Price/Cash Flow ratio (P/CF) is calculated by dividing the market price of a company's stock by its cash flow per share. It measures the company's stock value relative to its cash flow, and is sometimes said to be a more objective measure of a company's value because cash flows cannot be manipulated as easily as earnings, which considers non-cash items such as depreciation and amortization. KLBF's P/CF ratio of 31.52x is considered a relatively high ratio by analysts.
Max 2
Low
The Enterprise Value/Revenue ratio (EV/R) is calculated by dividing the enterprise value of a company by its revenue. It measures the company's enterprise value relative to its revenue. It is an indicator of how much it costs to buy the company's revenue; the lower the ratio, the cheaper the company's revenue. KLBF's EV/R ratio of 2.20x is considered fairly underpriced by the market The average EV/R ratio for the Pharmaceuticals & Health Care Research sector is 1.40x.
Max 3
Medium
Slightly Lower Intrinsic Value: Analyst's intrinsic value is of KLBF is IDR 1,088.63, which is 25% lower than KLBF's last closing price of IDR 1,480.00.
Max 3

Peers

KLBF Peers and Comparison

Peer Companies

Supertype Fuzzy Search
SymbolCompany Name
Market Cap
(in Trillion IDR)
Total Assets
(in Trillion IDR)
Total Revenue
(in Trillion IDR)
Profit and Loss
(in Trillion IDR)
P/E
P/B
KLBFKalbe Farma Tbk68.46T27.18T 30.31T 2.96T 23.123.31
MIKAPT Mitra Keluarga Karyasehat Tbk.39.22T7.11T 4.13T 0.95T 41.297.01
SILOPT Siloam International Hospitals Tbk.32.40T10.75T 10.83T 1.11T 29.294.28
SRAJSejahteraraya Anugrahjaya Tbk20.58T5.62T 2.35T -0.05T -433.0911.10
SIDOPT Industri Jamu Dan Farmasi Sido Muncul Tbk20.25T3.75T 3.61T 0.97T 20.865.94
HEALPT Medikaloka Hermina Tbk.19.03T8.52T 5.54T 0.48T 39.485.15
PRAYPT Famon Awal Bros Sedaya Tbk9.42T4.42T 1.70T 0.18T 53.643.42
TSPCTempo Scan Pacific Tbk9.09T11.31T 12.93T 1.41T 6.431.18
SOHOPT Soho Global Health Tbk6.24T4.67T 7.91T 0.34T 18.422.45
OMEDPT Jayamas Medica Industri Tbk5.33T2.46T 1.63T 0.22T 23.782.50
Competitiveness Recap of KLBF stock
WeightNotesScore
High
At a market cap of IDR 68,458.29 billion, KLBF.JK ranks 1 in Market Cap out of 10 companies in the Healthcare sector.●●
Max 2
High
At a PE of 23.12, KLBF.JK ranks 6 out of 10 companies in the Healthcare sector for P/E value. The average PE is -17.68 (unadjusted). A high P/E ratio often indicates higher growth expectation, or other qualitative factors that led investors to believe that the company has a defensible competitive advantage compared to its peers in Healthcare. In this regard, it trails behind sector leaders such as PT Famon Awal Bros Sedaya Tbk (53.64) in the Healthcare sector.
Max 2
Medium
At a PE of 23.12, KLBF.JK is trading at a higher PE than that of its subsector peers in Pharmaceuticals & Health Care Research (median of 8.87). false●●
Max 2
Medium
At a revenue of IDR 30.31 trillion, KLBF.JK ranks 1 in Revenue out of 10 companies in the Healthcare sector.●●
Max 2
Medium
At a profit of IDR 2.96 trillion, KLBF.JK ranks 1 in Profit out of 10 companies in the Healthcare sector.●●
Max 2

Future

Future Growth of KLBF

Growth Forecasts

KLBF 2024 Revenue Growth
+16.0%
KLBF 2024 EPS Growth
+4.2%
Sector Revenue Growth
-1.2%
Pharmaceuticals & Health Care Research
Indonesia Market Growth
+12.0%
IDX overall growth
Pharmaceuticals & Health Care Research Sector Revenue Growth '24
+11.1%
Healthcare Sector Revenue Growth '24
+17.1%

Sector Benchmark

Pharmaceuticals & Health Care Research companies in Indonesia are shrinking at a projected rate of -1.18% against the IDX average of +12.0%.

Pharmaceuticals & Health Care Research sector overview

KLBF Earnings & Revenue Forecast

All values in IDR billion

Future growth prospect of KLBF
WeightNotesScore
High
KLBF's projected growth rate of -1.18% is below the ID market average of 11.98%.●●●
Max 3
High
The Pharmaceuticals & Health Care Research sub-sector is projected to grow revenue by 11.14% in 2024. This number is higher than the previous year 2023's growth rate of 2.48%. This bodes well for KLBF's revenue growth prospects in the next 2 years. ●●
Max 3
Medium
The Pharmaceuticals & Health Care Research sub-sector is projected to increase earnings by 2.56% in 2024. This number is higher than the previous year 2023's EPS growth of -8.71%. false
Max 3
Medium
KLBF and its peers in the Pharmaceuticals & Health Care Research sub-sector belongs to the Healthcare sector. Companies in the Healthcare sector are projected to have a fruitful year heading into 2024. Specifically, earnings are projected to increase by 16.30% in 2024 while revenue growth is projected to increase by 17.10%. These macroeconomic trends will likely be a tailwind for KLBF's earnings growth prospects in the next 2 years. ●●
Max 3
Loading...
Loading...

Management

Executive Management

President Director

Vidjongtius15.2 years
Bernadus Karmin Winata
Director
Sie Djohan
Director
Mulialie
Director
Jos Iwan Atmadjaja
Director
Kartika Setiabudy
Director
NamePositionShares%
B. R. Irawati SetiadyCommissioner21,588,0000.05
MulialieDirector250,045< 0.01
Ronny HadianaCommissioner91,071,0070.19
Expressed in millions IDR, unless otherwise stated

Ownership

KLBF Ownership

Others
27.41%
Insiders
58.23%
Institutions
14.36%
NameNumber of SharesOwnership (%)Value
Public (Scripless)18,867,155,17840.2527,923.39B
Ladang Ira Panen, Pt4,903,185,74010.467,256.71B
Gira Sole Prima, Pt4,824,509,48510.297,140.27B
Santa Seha Sanadi, Pt 4,718,121,94010.076,982.82B
Diptanala Bahana, Pt4,454,807,0409.56,593.11B
Lucasta Murni Cemerlang, Pt4,439,895,4409.476,571.05B
Bina Arta Charisma, Pt3,842,039,0408.25,686.22B
Treasury Stock619,480,7001.32916.83B
Public (Scrip)93,018,4950.2137.67B
Ronny Hadiana91,071,0070.19134.79B
B. R. Irawati Setiady21,588,0000.0531.95B

Largest Institutional Buy

Capital Research and Management Company
Bought 31-12-2023
+73,750,000 shares
Capital Guardian Trust Company
Bought 31-12-2023
+24,750,000 shares
Capital International Inc
Bought 31-12-2023
+24,750,000 shares

Largest Institutional Sell

No data is available for KLBF at the moment.

Institutional Transactions

Tracking institutional transactions buying / selling of KLBF stock